tiprankstipranks
Arcutis Biotherapeutics Inc (ARQT)
NASDAQ:ARQT
US Market
ARQT
Arcutis Biotherapeutics
RESEARCH TOOLSreports
Want to see ARQT full AI Analyst Report?

Arcutis Biotherapeutics (ARQT) Stock News & Sentiment

971 Followers
Arcutis Earnings Call Signals Momentum Amid Headwinds
Premium
Company Announcements
Arcutis Earnings Call Signals Momentum Amid Headwinds
10d ago
ARQT
Arcutis Biotherapeutics: Buy Rating Reaffirmed as Zoryve Momentum Supports Growth Outlook; $35 Price Target Maintained
Premium
Ratings
Arcutis Biotherapeutics: Buy Rating Reaffirmed as Zoryve Momentum Supports Growth Outlook; $35 Price Target Maintained
14d ago
ARQT
Analyst Reiterates Buy on Arcutis as Zoryve Momentum, New Data Support Unchanged $34 Price Target
Premium
Ratings
Analyst Reiterates Buy on Arcutis as Zoryve Momentum, New Data Support Unchanged $34 Price Target
14d ago
ARQT
Arcutis Biotherapeutics Reaffirmed at Buy as Growth Outlook Strengthens; $36 Price Target Maintained
Premium
Ratings
Arcutis Biotherapeutics Reaffirmed at Buy as Growth Outlook Strengthens; $36 Price Target Maintained
14d ago
ARQT
Arcutis Biotherapeutics: Near-Term Cost Pressures but Intact Long-Term Growth Thesis Supports Buy Rating
Premium
Ratings
Arcutis Biotherapeutics: Near-Term Cost Pressures but Intact Long-Term Growth Thesis Supports Buy Rating
28d ago
ARQT
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
Premium
Company Announcements
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
2M ago
ARQT
Arcutis (ARQT) Earnings Call Signals Scaled Growth
Premium
Company Announcements
Arcutis (ARQT) Earnings Call Signals Scaled Growth
3M ago
ARQT
More ARQT News >

ARQT News on the Web

Suvretta Capital Management, LLC Increases Stake in Lexeo Therapeutics Inc
GuruFocus News
Neutral
Analysts Offer Insights on Healthcare Companies: Daiichi Sankyo Company (OtherDSKYF) and Arcutis Biotherapeutics (ARQT)
TipRanks News
Bullish
Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities
TipRanks News
Bullish
Why Arcutis Biotherapeutics Stock Is Sinking Today
TipRanks News
Bearish
Why Arcutis Biotherapeutics Stock Is Sliding Fast
TipRanks News
Bearish
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
The Motley Fool
Neutral
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)
GuruFocus News
Neutral
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS
rttnews
Neutral

News Score - Last 7 Days

Very Positive
ARQT
Sector Average
Media Buzz
This Week1 articles
Weekly Average4.5 articles
News Sentiment
This Week100%
Sector Average76%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ARQT’s Media Buzz Sentiment?
1 articles about ARQT were published this week. In an average week, 4.5 articles are published.
    What is ARQT’s weekly average amount of articles?
    In an average week, 4.5 articles about ARQT are published.
      What is ARQT’s News Sentiment?
      100% of articles about ARQT were positive this week, compared to its sector average of 76%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        CGENCompugen
        PROKProKidney
        ROIVRoivant Sciences
        Showing the stocks with the most bullish news sentiment over the past week